The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
Open accessAbstract
BACKGROUND: The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. METHODS: Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with non-dialysis-dependent CKD, anaemia and iron deficiency not receiving erythropoiesis-stimulating agents (ESAs). Patients were randomized (1:1:2) to intravenous (IV) ferric carboxymaltose (FCM), targeting a higher (400-600 µg/L) or lower (100-200 µg/L) ferritin or oral iron therapy. The primary end point was time to initiation of other anaemia management (ESA, other iron therapy or blood transfusion) or haemoglobin (Hb) trigger of two consecutive values <10 g/dL during Weeks 8-52. RESULTS: The primary end point occurred in 36 patients (23.5%), 49 patients (32.2%) and 98 patients (31.8%) in the high-ferritin FCM, low-ferritin FCM and oral iron groups, respectively [hazard ratio (HR): 0.65; 95% confidence interval (CI): 0.44-0.95; P = 0.026 for high-ferritin FCM versus oral iron]. The increase in Hb was greater with high-ferritin FCM versus oral iron (P = 0.014) and a greater proportion of patients achieved an Hb increase ≥1 g/dL with high-ferritin FCM versus oral iron (HR: 2.04; 95% CI: 1.52-2.72; P < 0.001). Rates of adverse events and serious adverse events were similar in all groups. CONCLUSIONS: Compared with oral iron, IV FCM targeting a ferritin of 400-600 µg/L quickly reached and maintained Hb level, and delayed and/or reduced the need for other anaemia management including ESAs. Within the limitations of this trial, no renal toxicity was observed, with no difference in cardiovascular or infectious events. CLINICALTRIALSGOV NUMBER: NCT00994318.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
Self-citationA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Self-citationBesarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., Patel, U. D., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.295 · Cited by 526
Erythropoietic response and outcomes in kidney disease and type 2 diabetes
Solomon, S. D., Uno, H., Lewis, E. F., Eckardt, K.-U., Lin, J., Burdmann, E. A., de Zeeuw, D., Ivanovich, P., Levey, A. S., Parfrey, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005109 · Cited by 473
Self-citationA randomized controlled study of iron supplementation in patients treated with erythropoietin
Macdougall, I. C., Tucker, B., Thompson, J., Tomson, C. R. V., Baker, L. R. I., & Raine, A. E. G. (1996) · Kidney International · doi:10.1038/ki.1996.487 · Cited by 417
Self-citationMeta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Tonelli, M., Garg, A. X., Pellegrini, F., Ravani, P., Jardine, M., Perkovic, V., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-1-201007060-00252 · Cited by 363
Shepshelovich, D., Rozen-Zvi, B., Avni, T., Gafter, U., & Gafter-Gvili, A. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.04.018 · Cited by 322
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin
Fishbane, S., & Berns, J. S. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00532.x · Cited by 289
Ferumoxytol for Treating Iron Deficiency Anemia in CKD
Spinowitz, B. S., Kausz, A. T., Baptista, J., Noble, S. D., Sothinathan, R., Bernardo, M. V., Brenner, L., & Pereira, B. J. G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101156 · Cited by 262
Van Wyck, D. B., Roppolo, M., Martinez, C. O., Mazey, R. M., & Mcmurray, S. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00758.x · Cited by 226
Self-citationGreater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients
Kilpatrick, R. D., Critchlow, C. W., Fishbane, S., Besarab, A., Stehman-Breen, C., Krishnan, M., & Bradbury, B. D. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04601007 · Cited by 206
Qunibi, W. Y., Martinez, C., Smith, M., Benjamin, J., Mangione, A., & Roger, S. D. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq613 · Cited by 184
Self-citationParenteral versus oral iron therapy for adults and children with chronic kidney disease
Albaramki, J., Hodson, E. M., Craig, J. C., & Webster, A. C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007857.pub2 · Cited by 168
Rozen-Zvi, B., Gafter-Gvili, A., Paul, M., Leibovici, L., Shpilberg, O., & Gafter, U. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.05.033 · Cited by 163
Charytan, C., Qunibi, W. Y., & Bailie, G. R. (2005) · Nephron Clinical Practice · doi:10.1159/000085049 · Cited by 129
Minutolo, R., Locatelli, F., Gallieni, M. A., Bonofiglio, R., Fuíano, G., Oldrizzi, L., Conte, G., Nicola, L. D., Mangione, F., Esposito, P. B., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft338 · Cited by 90
Vaziri, N. D. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.10.027 · Cited by 82
Charytan, C., Bernardo, M. V., Koch, T. A., Butcher, A., Morris, D., & Bregman, D. B. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs528 · Cited by 77
Iron therapy in the pediatric hemodialysis population
Brugnara, C., Dahl, N. V., Watkins, S. L., Warady, B. A., Kausz, A., Lerner, G. R., Brewer, E. D., & Chadha, V. (2004) · Pediatric Nephrology · doi:10.1007/s00467-004-1457-5 · Cited by 63
Changing Patterns of Anemia Management in US Hemodialysis Patients
Freburger, J. K., Ng, L. J., Bradbury, B. D., Kshirsagar, A. V., & Brookhart, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.03.011 · Cited by 59
Chapter 2: Use of iron to treat anemia in CKD
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.34 · Cited by 50
Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K., Gaillard, S., Wyck, D. V., Roubert, B., Cushway, T., Roger, S. D., & on Behalf of the FIND-CKD Study Investigators (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft424 · Cited by 43
Self-citationRed blood cell transfusion use in patients with chronic kidney disease
Gill, K., Muntner, P., Lafayette, R. A., Petersen, J., Fink, J. C., Gilbertson, D. T., & Bradbury, B. D. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs580 · Cited by 42
[Iron supplementation during erythropoietin therapy in patients on hemodialysis].
Švára, F., Sulková, S., Kvasnička, J., & Polakovič, V. (1996) · PubMed · Cited by 9
Cited by
Camaschella, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1401038 · Cited by 1,678
Weiss, G., Ganz, T., & Goodnough, L. T. (2019) · Blood · doi:10.1182/blood-2018-06-856500 · Cited by 1,219
Camaschella, C. (2019) · Blood · doi:10.1182/blood-2018-05-815944 · Cited by 702
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
Self-citationHow the Target Hemoglobin of Renal Anemia Should Be?
Mimura, I., Tanaka, T., & Nangaku, M. (2015) · Nephron · doi:10.1159/000440849 · Cited by 416
Metadata
- Authors
- Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K.-U., Gaillard, C., Van Wyck, D., Roubert, B., Nolen, J. G., Roger, S. D., & on behalf of the FIND-CKD Study Investigators
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06-02
- Volume
- 29
- Issue
- 11
- Pages
- 2075-2084
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2116948290
- Cited by
- 328
- References
- 27
- FWCI
- 19.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.